About Patheon N.V. (NYSE:PTHN)
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.
Industry, Sector and Symbol
SymbolNYSE:PTHNPrevious Symbol: NASDAQ:PTHN
Trailing P/E Ratio45.43
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$1.87 billion
Price / Sales2.72
Price / CashN/A
Book Value($2.40) per share
Price / Book-14.58
Net Income$31.70 million
Return on Equity-35.93%
Return on Assets4.18%
Frequently Asked Questions for Patheon N.V. (NYSE:PTHN)
What is Patheon N.V.'s stock symbol?
Patheon N.V. trades on the New York Stock Exchange (NYSE) under the ticker symbol "PTHN."
How were Patheon N.V.'s earnings last quarter?
Patheon N.V. (NYSE:PTHN) released its quarterly earnings results on Thursday, June, 8th. The company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.19 by $0.01. The business earned $483.40 million during the quarter, compared to analysts' expectations of $466.08 million. Patheon N.V. had a negative return on equity of 35.93% and a net margin of 5.63%. The firm's revenue was up 3.2% on a year-over-year basis. View Patheon N.V.'s Earnings History.
Where is Patheon N.V.'s stock going? Where will Patheon N.V.'s stock price be in 2017?
7 Wall Street analysts have issued 12 month price targets for Patheon N.V.'s shares. Their forecasts range from $28.00 to $35.00. On average, they expect Patheon N.V.'s share price to reach $33.60 in the next twelve months. View Analyst Ratings for Patheon N.V..
Who are some of Patheon N.V.'s key competitors?
Some companies that are related to Patheon N.V. include Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Taro Pharmaceutical Industries (TARO), Akorn (AKRX), BTG plc (BTG), Opko Health (OPK), Hikma Pharmaceuticals PLC (HIK), Horizon Pharma PLC (HZNP), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Pacira Pharmaceuticals (PCRX), Emergent Biosolutions (EBS), Cambrex Corporation (CBM), Theravance Biopharma (TBPH), Innoviva (INVA), Impax Laboratories (IPXL) and Akcea Therapeutics (AKCA).
Who are Patheon N.V.'s key executives?
Patheon N.V.'s management team includes the folowing people:
- Paul S. Levy, Chairman of the Board
- James C. Mullen, Chief Executive Officer, Director
- Stuart R. Grant, Chief Financial Officer, Executive Vice President
- Gilles A. Cottier, President - Global Pharmaceutical Development Services
- Franco Negron, President - Drug Product Services
- Lukas Utiger, President - Drug Substance
- Michael J. Lehmann, Executive Vice President - Global Sales and Marketing
- Michael E. Lytton J.D., Executive Vice President - Corporate Development and Strategy
- Rebecca Holland New, Chief Human Resources Officer and Executive Vice President - Communications and Project Management Office
- Harry R. Gill III, Senior Vice President - Quality and Continuous Improvement
When did Patheon N.V. IPO?
(PTHN) raised $625 million in an initial public offering (IPO) on Thursday, July 21st 2016. The company issued 30,500,000 shares at $19.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies, UBS Investment Bank, Credit Suisse, Evercore ISI and Wells Fargo Securities served as the underwriters for the IPO and Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners were co-managers.
Who owns Patheon N.V. stock?
Patheon N.V.'s stock is owned by many different of institutional and retail investors. Top institutional shareholders include
THERMO FISHER SCIENTIFIC INC.
(99.00%). Company insiders that own Patheon N.V. stock include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman. View Institutional Ownership Trends for Patheon N.V..
How do I buy Patheon N.V. stock?
Shares of Patheon N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Patheon N.V.'s stock price today?
One share of Patheon N.V. stock can currently be purchased for approximately $34.98.
How big of a company is Patheon N.V.?
Patheon N.V. has a market capitalization of $5.08 billion and generates $1.87 billion in revenue each year. The company earns $31.70 million in net income (profit) each year or $0.75 on an earnings per share basis. Patheon N.V. employs 9,100 workers across the globe.
How can I contact Patheon N.V.?
Patheon N.V.'s mailing address is Herengracht 483, Amsterdam P7, 1017BT. The company can be reached via phone at 31-20-622-3243.
MarketBeat Community Rating for Patheon N.V. (PTHN)MarketBeat's community ratings are surveys of what our community members think about Patheon N.V. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Patheon N.V. (NYSE:PTHN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 6 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.14)|
|Consensus Price Target: ||$33.60 (3.95% downside)|
Consensus Price Target History for Patheon N.V. (NYSE:PTHN)
Analysts' Ratings History for Patheon N.V. (NYSE:PTHN)
(Data available from 11/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/21/2017||Jefferies Group LLC||Reiterated Rating||Hold||$35.00||Low|
|6/9/2017||Leerink Swann||Downgrade||Outperform -> Market Perform||$31.00 -> $35.00||Low|
|6/9/2017||Raymond James Financial, Inc.||Downgrade||Outperform -> Mkt Perform||Low|
|6/8/2017||J P Morgan Chase & Co||Downgrade||Overweight -> Neutral||Low|
|5/15/2017||William Blair||Downgrade||Outperform -> Market Perform||Low|
|5/15/2017||Piper Jaffray Companies||Downgrade||Overweight -> Neutral||Low|
|3/17/2017||Robert W. Baird||Downgrade||Outperform -> Neutral||$34.00 -> $28.00||Low|
|8/16/2016||Credit Suisse Group||Initiated Coverage||Neutral||$30.00||N/A|
|8/15/2016||Wells Fargo & Company||Initiated Coverage||Outperform||N/A|
|8/15/2016||Morgan Stanley||Initiated Coverage||Overweight||$31.00||N/A|
Earnings History and Estimates Chart for Patheon N.V. (NYSE:PTHN)
Earnings History by Quarter for Patheon N.V. (NYSE PTHN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|6/8/2017||4/30/2017||$0.19||$0.20||$466.08 million||$483.40 million||View||N/A|
|3/16/2017||1/31/2017||$0.22||$0.14||$463.39 million||$457.40 million||View||N/A|
|12/20/2016||Q416||$0.39||$0.30||$496.27 million||$510.20 million||View||N/A|
Earnings Estimates for Patheon N.V. (NYSE:PTHN)
Current Year EPS Consensus Estimate: $1.03 EPS
Dividend History for Patheon N.V. (NYSE:PTHN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Patheon N.V. (NYSE PTHN)
Insider Ownership Percentage: 0.14%
Institutional Ownership Percentage: 12.23%
Insider Trades by Quarter for Patheon N.V. (NYSE PTHN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/30/2016||Paul S Levy||Director||Buy||10,000||$29.55||$295,500.00|| |
|9/28/2016||Paul S Levy||Director||Buy||15,000||$29.64||$444,600.00|| |
|9/12/2016||Paul S Levy||Director||Buy||37,000||$28.01||$1,036,370.00|| |
|7/26/2016||Jll Patheon Co-Investment Fund||Major Shareholder||Buy||815,730||$19.85||$16,192,240.50|| |
|7/26/2016||Pamela Daley||Director||Buy||48,800||$19.85||$968,680.00|| |
|7/21/2016||Philip Eykerman||Director||Buy||28,000||$25.00||$700,000.00|| |
Latest Headlines for Patheon N.V. (NYSE PTHN)
Financials are not available for this stock.
Patheon N.V. (NYSE PTHN) Chart for Friday, November, 24, 2017